Aim To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
www.cmj.hr > doi: 10 .3325/cmj.2008. 2.192 Basic Science Basic Science CD137, a member of the tumor necrosis factor receptor family, is expressed primarily on activated T lymphocytes and natural killer cells (1, 2) . In contrast, its ligand CD137L is mainly expressed on antigen-presenting cells, such as mature dendritic cells, activated B cells, and macrophages (3, 4) . The co-stimulation through CD137/CD137L enhances T cell activation, promotes the rejection of cardiac allografts and skin transplants, and eradicates experimentally induced tumors in mice (5) (6) (7) (8) (9) (10) .
However, expression of human CD137 and CD137L is not restricted to immune cells, and the functions of human CD137/ CD137L pathway are more complex than that of mice. Expression of CD137 protein has been verified in chondrocytes (11) and on blood vessel walls in primary malignant tumors (12) . Expression of CD137L has also been found on several human carcinoma cell lines and its function has been analyzed in vitro. On the one hand, CD137L expressed on carcinoma cells could function as a co-stimulatory molecule of T cell activation for the production of cytokines, most notably interferon-gamma (IFN-γ), in co-culture of T cells and tumor cells. On the other hand, incubation of tumor cells expressing CD137L with a CD137-Ig fusion protein leads to the production of interleukin-8 (IL-8) of tumor cells (13) .
Up to now, however, no studies have reported the expression of CD137L in human primary tumors. Therefore, the aim of this study was to assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
Materials and methods

Cell lines
Human tumor cell lines -HepG2.2.15 (hepatocarcinoma integrated with whole hepatitis B virus genome), BEL7402 (hepatocarcinoma), HLE (hepatocarcinoma), HT29 (colon adenocarcinoma), L78 (lung squamous carcinoma), A2 (lung adenocarcinoma), U937 (histocytic lymphoma), HL60 (promyelocytic leukemia), and ECV304 (embryonic venous endotheliocytes) -were purchased from Medical Science Institute of Shandong Province. H6 (colon carcinoma) tumor cell line was kindly provided by Professor Jiayou Zhang from the University of Kentucky, USA.
To obtain Chinese hamster ovary (CHO) cells expressing membrane CD137, CD137-CHO cells (CHO transfected with human CD137 gene) were transfected as follows: the recombinant CD137-pCDNA3 plasmid (containing human CD137 cDNA sequence) and pSV2-dhfr plasmid were co-transfected into dhfr-CHO cells by lipid-mediated transfection. The positive clones were selected by 400 μg/mL G418. Expression of human membrane CD137 on dhfr-CHO cells was induced by raising the concentration of methotrexate. CD137 mRNA and protein were determined by reverse transcription polymerase chain reaction (RT-PCR), immunocytochemistry, and flow cytometry (14) .
Cell culture
Tumor cell lines U937, HL60, HLE, HT29, A2, and L78 were routinely cultured in Roswell Park Memorial Institute medium (RPMI) 1640 supplemented with 10% fetal calf serum (FCS; Hangzhou Sijiqing, China) and 1% penicillin/streptomycin (Sigma, St. Louis, MO, USA); ECV304 and H6 were cultured in DMEM, and BEL7402 were cultured in MEM with the same supplements; HepG2.2.15 were cultured in MEM supplemented with 10% FCS and 380 ng/mL G418 (Sigma). CD137-CHO cells were cultured in F12 medium containing 10% FCS and G418. Human peripheral blood mononuclear cells were isolated from peripheral blood derived from healthy donors by Ficoll density gradient centrifugation.
Surgical specimens
A total of 63 tissue specimens were obtained from patients who underwent operations at Qilu Hospital, Shandong University, China, from 2000 to 2004. Pathological diagnosis including tumor differentiation grade was made according to the recent World Health Organization criteria for different tumors by clinical pathologists (15) (16) (17) . Malignant tumors were divided into three differentiation grades as follows: high differentiation, moderate differentiation, and low differentiation. Twelve specimens of normal tissue were excised from patients who were initially suspected to have a tumor but were later diagnosed as healthy. The tissue types and tumor differentiation grades are presented in Table 1 . This study was conducted in full compliance with the national legislation and the ethical standards of the Chinese Medical Association. Informed consent was obtained from all patients before the biopsy.
Determination of CD137 or CD137L expression by immunohistochemistry
Fresh tissue specimens were frozen for 1 hour after the biopsy, then 4-6 μm-thick frozen sections were prepared at -20°C and fixed in acetone for 10 minutes at 4°C. Immunohistochemical staining for CD137 or CD137L expression was performed using an ABC kit (Boshide Company, Wuhan, China) according to the manufacturer's instructions. The sections were exposed to 0.3% hydrogen peroxide-methanol solution to quench endogenous peroxidase activity. After a 30-minute pre-incubation with normal goat serum, sections were incubated with anti-CD137 mAbs (5 µg/mL, BD Pharmingen Inc., San Diego, CA, USA) or anti-CD137L mAbs (4 µg/ml, BD Pharmigen Inc.) for 30 minutes, followed by biotinylated goat anti-mouse IgG, and avidin-biotin-peroxidase complex; diaminobenzidine (Boshide Company) was used as a peroxidase substrate. All incubations were performed at room temperature. As negative control, primary mAb was replaced with an isotypematched antibody with irrelevant specificity. Three random sections were examined.
Expression of CD137 or CD137L was assessed by two independent pathologists who were blinded to the patient's outcome. The immunoreactivity results were presented as either "negative" (percentage of CD137 or CD137L staining was 0%-10%) or "positive" (percentage of CD137 or CD137L staining was >10%).
Assessment of CD137L expression by RT-PCR
CD137L mRNA expression in various cells was detected using RT-PCR. Briefly, total RNA was extracted from the cells using TRIZOL (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized using Superscript preamplification system (Promega, Madison WI, USA) and PCR amplification was performed using the following primers (designed based on literature and synthesized by Shanghai Shenggong, China): human β-actin sense primer: 5'ACA CTG TGC CCA TCT ACG AGG GG 3′; anti-sense primer: 5'ATG ATG GAG TTG AAG GTA GTT TCG TGG AT 3′, human CD137L sense primer: 5'GTT TCA CTT GCG CTG CAC CTG CAG CCA CTG 3′; anti-sense primer: 5'GGC TCT AGA TAT CAA GGT CCA ACT TGG GA AGG 3′. After denaturation at 94°C for 5 minutes, 30 PCR cycles were performed using human CD137L specific primers, each consisting of a denaturation step (94°C, 1 minute), an annealing step (52°C, 2 minutes), and an elongation step (72°C, 2 minutes), followed by an extension at 72°C for 5 minutes. The products were detected by electrophoresis on 2% agarose gel containing ethidium bromide and analyzed using Imagemaster Gel Analysis Software (Amersham Pharmacia Biotech, Uppsala, Sweden). The expression levels of CD137L mRNA were compared after normalizing OD value to β-actin, which was defined as the ratio of OD CD137L /OD β-actin .
Measurement of cytokines by ELISA
T cells were purified from peripheral blood using Rosettesep TM Antibody Cocktail (Senxiong Company, Shanghai, China). Briefly, 250 μL of RosetteSep TM cocktail was added per 5 mL of peripheral blood, mixed, and incubated at room temperature for 20 minutes. Next, the sample was diluted with phosphate buffer saline containing 2% FCS. The diluted sample was then layered on top of Ficoll-Paque at a 1:2 dilution and then centrifuged for 20 minutes at 2000 r/min at room temperature. Enriched T cells were harvested from the plasma-Ficoll interface and washed twice with phosphate buffer saline containing 2% FCS. The purity of T cells detected by flow cytometry was >95%.
Tumor cells L78 or HepG2.2.15 were cultured in 96-well plates at 37°C, 5% CO 2 in a volume of 200 μL with different concentration (1 × 10 6 /mL, 5 × 10 5 /mL, 1 × 10 5 /mL), respectively. After 48 hours the supernatant was discarded, purified T cells (5 × 10 5 /mL) were added in a volume of 200 μL in the presence or absence of anti-CD3 mAb (10 μg/mL, BD Pharmingen), or with anti-CD137L mAb (5 μg/mL, BD Pharmingen). After incubation for 48 hours, the supernatant was collected and IFN-γ was detected by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Senxiong Company). Briefly, the supernatant was added into 96-well plates coated with anti-IFN-γ antibody in duplicate and incubated at 37°C for 2 hours. Human recombinant IFN-γ was included as standard. After six washes, biotinylated anti-IFN-γ antibody was added and incubated at 37°C for 1 hour; avidin-conjugated horseradish peroxidase (HRP) was added for an additional 1 hour at 37°C, followed by the substrate working solution until color development. Six phosphate buffer saline washes were performed between steps, and plates were read at OD 492 nm using an automated microtiter plate reader (Bio-Rad, Hercules, CA, USA).
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Statistical analysis
The t test and ANOVA (Turkey-Kramer multiple comparisons test) were used to assess the statistical significance. P<0.050 was considered significant. All calculations were per-formed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA).
Results
Human primary tumor tissues express CD137 and
CD137L at different locations
Both CD137 and CD137L expression was detected in human benign or malignant tumor tissues but not in normal tissues (Table  2 ). CD137L was expressed on tumor cells, whereas CD137 was detected on endothelial cells and smooth muscle cells of tumor vessel walls (Figure 1 ). In addition, tumors expressing CD137 also expressed CD137L, whereas some tumors expressing CD137L did not show detectable CD137 (Table 2) . Though the samples were derived from many different tissue types, expression of CD137 or CD137L was more often found in malignant tumors, especially in moderate or low-differentiated tumors. Only a few benign tumors expressed CD137 and CD137L, as opposed to about a half of malignant tumors (Table 3) . Among malignant tumors, CD137 or CD137L expression in moderate or low-differentiated malignant tumors was higher than in highly differentiated tumors.
Human tumor cell lines express high levels of
CD137L
Our results showed that tumor cells in human primary tumor tissues expressed CD137L. We also detected CD137L expression in human tumor cell lines derived from different primary tissues by RT-PCR. Normal unstimulated peripheral blood mononuclear cells did not express CD137L mRNA but all investigated tumor cell lines (HepG2.2.15, BEL7402, HLE, HT29, L78, A2, U937, HL60, and H6) showed high levels of CD137L expression ( Figure 2) . Unexpectedly, non-tumor cell line, embryonic venous endotheliocytes ECV304, also expressed CD137L. These results indicated that CD137L was not only expressed in primary tumors but also in tumor cell lines and some non-tumor cell lines, suggesting CD137L expression may be related to rapid cell growth.
CD137L expressed on tumor cells is functional
To investigate the role of CD137L on tumor cells, we co-cultured tumor cells L78 or HepG2.2.15 expressing CD137L with activated human T cells in the presence of anti-CD3 mAb to stimulate T cell to express CD137. We detected IFN-γ secreted by T cells using ELISA. In the presence of anti-CD3 mAb, CD137-expressing T cells co-cultured with L78 cells produced higher levels of IFN-γ than CD137-lacking T cells (in the absence of anti-CD3 mAb) (P<0.001), depending on the tumor cell number (data not shown). After blocking CD137/CD137L pathway using anti-CD137L mAb, the levels of IFN-γ significantly decreased (P<0.001), compared with control IgG. However, there was no obvious change of IFN-γ secretion when T cells were incubated with or without HepG2.2.15 cells (in the presence or absence of anti-CD3 mAb) (P = 0.375) ( Figure  3 ). This suggests that CD137L on L78 cells could conduct a co-stimulatory signal into T cells and this action could be specifically blocked by anti-CD137L mAb.
To confirm whether CD137L expressed on tumor cells could also signal back into tumor cells, HepG2.2.15, or A2 cells were co-cultured with fixed CD137-CHO cells expressing CD137, respectively, and IL-8 in the supernatant was detected by ELI-SA. Ligation of CD137L on tumor cells by CD137 expressed on CD137-CHO cells elevated the levels of IL-8 produced by HepG2.2.15 cells (P = 0.038). However, the action of CD137L on A2 cells was weak ( Figure 4 ).
Discussion
We showed that both CD137 and CD137L were simultaneously expressed in human primary tumor tissues, but on different locations. CD137 was expressed on the vessel walls in tumor tissues, whereas CD137L was expressed on tumor cells. The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors. Furthermore, we found that CD137L expressed on tumor cells was functional in several ways. On the one hand, ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells caused T cells to produce high levels of IFN-γ. On the other hand, ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 caused tumor cells to produce IL-8. The CD137/CD137L pathway provides an important co-stimulatory signal for the activation and proliferation of T cells as well as a reverse signal for IL-8 production by macrophages or tumor cells (6, (18) (19) (20) (21) (22) . Ligation of the CD137 molecule with CD137L or anti-CD137 antibody can stimulate the activation and proliferation of CD4 + and CD8 + T cells in vitro. In mice model, administration of anti-CD137 antibody eradicates experimentally induced tumors and CD137L on the tumor cell line or CD137L fusion proteins stimulates an effective anti-tumor immunity, suggesting that CD137L may be a target molecule for tumor therapy (8, 9, 23, 24) . To the best of our knowledge, our results are the first demonstration that human primary tumor tissues express CD137L and that low-differentiated malignant tumor tissues show a high rate of CD137L, while normal tissues do not. Our results and Salih's report (13) also indicate that CD137L is constitutively expressed on carcinoma cell line. Although CD137L on tumor cells L78 could enhance IFN-γ secretion by T cells, its action was weak. Nota- bly, CD137L on tumor cells HepG2.2.15 also triggered them to produce IL-8. As a multifunctional cytokine, IL-8 is initially characterized for its leukocyte chemotactic activity but now is known to possess tumorigenic and proangiogenic properties as well. IL-8 is critical to the development and progression of numerous malignancies through angiogenesis (25) . Therefore, whether human CD137L can be a target molecule for tumor therapy and what is the influence of CD137L on T cell-tumor cell interaction in vivo remains to be clarified.
Although CD137 and CD137L were often simultaneously expressed in the same tumor tissue samples, their expression locations were different. CD137L was expressed on tumor cells, while CD137 was expressed on endothelial cells or smooth muscle cells of the vessel walls within tumor tissues, which is consistent with the previous report by Broll et al (12) . However, the significance of CD137 in tumor tissues is unknown. Broll et al (12) speculated that CD137 on the endothelium could cause monocyte activation and may contribute to monocyte extravasation into the tissue. We propose the hypothesis that the interaction of CD137 on the endothelium with CD137L on tumor cells may promote tumor progression based on the following evidence. First, CD137L on some tumor cells could trigger tumor cells to produce IL-8, which is critical for the development and progression of numerous malignancies (25) . Second, CD137 and CD137L were only expressed in benign or malignant tumors simultaneously but not in normal tissues, and their expressions were more common in malignant tumors, especially in moderate or low-differentiated tumors. However, more investigation remains to be done.
Taken together, we demonstrated that the expression of CD137 and CD137L was observed only in human benign or malignant tumors but not in normal tissues. CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells. The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors. Furthermore, we found that CD137L expressed on tumor cells was functional. These data suggest that CD137 and CD137L expressed in human tumor tissues may influence tumor immunity during its progression.
